Barry Investment Advisors LLC Has $5.34 Million Holdings in Pfizer Inc. (NYSE:PFE)

Barry Investment Advisors LLC increased its position in Pfizer Inc. (NYSE:PFE) by 1.1% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 192,573 shares of the biopharmaceutical company’s stock after acquiring an additional 2,123 shares during the quarter. Pfizer comprises about 1.8% of Barry Investment Advisors LLC’s investment portfolio, making the stock its 21st biggest position. Barry Investment Advisors LLC’s holdings in Pfizer were worth $5,344,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. Advisor OS LLC raised its position in shares of Pfizer by 1.0% during the fourth quarter. Advisor OS LLC now owns 35,202 shares of the biopharmaceutical company’s stock valued at $1,013,000 after buying an additional 365 shares during the last quarter. Safeguard Investment Advisory Group LLC grew its holdings in shares of Pfizer by 3.9% during the 4th quarter. Safeguard Investment Advisory Group LLC now owns 9,987 shares of the biopharmaceutical company’s stock worth $288,000 after purchasing an additional 371 shares in the last quarter. Lantz Financial LLC lifted its position in Pfizer by 1.3% in the first quarter. Lantz Financial LLC now owns 30,582 shares of the biopharmaceutical company’s stock worth $849,000 after purchasing an additional 381 shares during the period. King Wealth Management Group boosted its stake in Pfizer by 2.4% during the fourth quarter. King Wealth Management Group now owns 16,686 shares of the biopharmaceutical company’s stock worth $480,000 after buying an additional 388 shares in the last quarter. Finally, Advance Capital Management Inc. raised its stake in shares of Pfizer by 4.0% in the 4th quarter. Advance Capital Management Inc. now owns 10,177 shares of the biopharmaceutical company’s stock valued at $293,000 after buying an additional 391 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on PFE shares. BMO Capital Markets reaffirmed an “outperform” rating and set a $36.00 price objective (up from $33.00) on shares of Pfizer in a report on Thursday, May 2nd. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research note on Wednesday, June 26th. Morgan Stanley lifted their price target on shares of Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a report on Thursday, May 2nd. Finally, Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Nine analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $35.54.

Pfizer Trading Up 0.6 %

NYSE PFE opened at $27.98 on Monday. The company has a current ratio of 1.05, a quick ratio of 0.78 and a debt-to-equity ratio of 0.66. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $37.80. The company has a market capitalization of $158.55 billion, a PE ratio of -466.26, a P/E/G ratio of 1.10 and a beta of 0.69. The stock has a 50-day simple moving average of $27.90 and a 200 day simple moving average of $27.69.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, beating analysts’ consensus estimates of $0.56 by $0.26. The business had revenue of $14.88 billion for the quarter, compared to the consensus estimate of $13.87 billion. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. Pfizer’s revenue for the quarter was down 19.5% on a year-over-year basis. During the same period last year, the company posted $1.23 EPS. Research analysts forecast that Pfizer Inc. will post 2.38 EPS for the current year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th will be issued a $0.42 dividend. This represents a $1.68 annualized dividend and a dividend yield of 6.00%. The ex-dividend date of this dividend is Thursday, July 25th. Pfizer’s dividend payout ratio (DPR) is -2,799.53%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.